FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308383485> ?p ?o ?g. }

• W4308383485 abstract "<h3>Background</h3> Best practice in surveillance imaging for survivors after immune checkpoint inhibitors (CPI) remain poorly defined for stage 3-4 aMEL; KPNC oversees care for 4 million patients and has 300 new diagnoses of aMEL per year. Follow-up after CPI is coordinated in KPNC via care pathways using national guidelines. <h3>Methods</h3> We report a retrospective study of patients treated between 2014 and 2018 for aMEL with CPI. Data was obtained by chart review. Patients were included who received anti-PD1, anti-CTLA4, or combination; had ≥1 dose of any-line palliative (pTX) or adjuvant therapy (adjTX); and had ≥1 year of follow-up after treatment, and imaging response (SD/PR/CR) or >=6 months without recurrence if after adjTX. Symptomatic versus asymptomatic progression was defined by evidence of documentation of symptoms at time of imaging. Events from patients who had >1 line of CPI therapy were counted separately. Log-rank test was used to determine Kaplan-Meier survival estimates, and rates were calculated per 100 person-months. <h3>Results</h3> 176 patients met inclusion criteria. These patients underwent 191 lines of therapy (69 adjTx and 122 pTX). Progression after therapy occurred in 29 lines of treatment (42%) after adjTX, of these 62% were symptomatic. 51 (41.8%) patients relapsed after pTX and 44% were symptomatic. Comparing asymptomatic and symptomatic progression, there were no differences in risk of relapse after adjTX (p=.14) or pTX (p=0.73). Within adjTX, patients with asymptomatic recurrences had lower all-cause mortality (ACM) than those with symptoms (Relative Risk (RR) 0.6 [0.0-1.3] vs 1.9 [0.8-3.0], p=.03) and lower melanoma-specific mortality (MSM) (RR 0.2 [0.0-0.6] vs 1.2 [0.3-2.1], p=0.03 for MSM). No differences were detected for ACM and MSM for patients receiving in pTX with asymptomatic versus symptomatic recurrence (ACM RR 1.9 (1.0-2.9) in asymptomatic recurrence vs 2.8 (1.4-4.2) in symptomatic, p=0.15 for ACM and; MSM RR 1.6 (0.7-2.4) vs 2.4 (1.2-3.7), p=0.12 for MSM). There were differences in ACM (p=0.02) and MSM survival (p=0.01) in adjTX but not in pTX (ACM p=0.90; MSM p=0.79). <h3>Conclusions</h3> Our study finds identification of asymptomatic relapse has survival benefit in the curative setting but not for aMEL treated with palliative intent. This finding is likely because curative therapy can be offered if relapse is identified early for resectable disease. Our study findings suggests a symptom-based imaging surveillance strategy similar to that used in histologies with effective systemic therapy is effective (e.g. lymphoma, breast cancer) could potentially be used for melanoma. Prospective study is needed to further guide clinical practice." @default.
• W4308383485 created "2022-11-11" @default.
• W4308383485 creator A5019662030 @default.
• W4308383485 creator A5021722382 @default.
• W4308383485 creator A5032920001 @default.
• W4308383485 creator A5056126942 @default.
• W4308383485 creator A5079039743 @default.
• W4308383485 creator A5086118815 @default.
• W4308383485 date "2022-11-01" @default.
• W4308383485 modified "2023-09-25" @default.
• W4308383485 title "937 Post-immunotherapy survivorship in advanced melanoma (aMEL): routine versus symptom-based imaging surveillance, a retrospective review in a large integrated healthcare network, Kaiser Permanente Northern California (KPNC)" @default.
• W4308383485 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0937" @default.
• W4308383485 hasPublicationYear "2022" @default.
• W4308383485 type Work @default.
• W4308383485 citedByCount "0" @default.
• W4308383485 crossrefType "proceedings-article" @default.
• W4308383485 hasAuthorship W4308383485A5019662030 @default.
• W4308383485 hasAuthorship W4308383485A5021722382 @default.
• W4308383485 hasAuthorship W4308383485A5032920001 @default.
• W4308383485 hasAuthorship W4308383485A5056126942 @default.
• W4308383485 hasAuthorship W4308383485A5079039743 @default.
• W4308383485 hasAuthorship W4308383485A5086118815 @default.
• W4308383485 hasBestOaLocation W43083834851 @default.
• W4308383485 hasConcept C126322002 @default.
• W4308383485 hasConcept C167135981 @default.
• W4308383485 hasConcept C2777910003 @default.
• W4308383485 hasConcept C71924100 @default.
• W4308383485 hasConcept C72563966 @default.
• W4308383485 hasConceptScore W4308383485C126322002 @default.
• W4308383485 hasConceptScore W4308383485C167135981 @default.
• W4308383485 hasConceptScore W4308383485C2777910003 @default.
• W4308383485 hasConceptScore W4308383485C71924100 @default.
• W4308383485 hasConceptScore W4308383485C72563966 @default.
• W4308383485 hasLocation W43083834851 @default.
• W4308383485 hasOpenAccess W4308383485 @default.
• W4308383485 hasPrimaryLocation W43083834851 @default.
• W4308383485 hasRelatedWork W1975271362 @default.
• W4308383485 hasRelatedWork W1987215768 @default.
• W4308383485 hasRelatedWork W1995188757 @default.
• W4308383485 hasRelatedWork W2016679923 @default.
• W4308383485 hasRelatedWork W2057721052 @default.
• W4308383485 hasRelatedWork W2116001782 @default.
• W4308383485 hasRelatedWork W2314711404 @default.
• W4308383485 hasRelatedWork W2423950151 @default.
• W4308383485 hasRelatedWork W2763646354 @default.
• W4308383485 hasRelatedWork W4229900919 @default.
• W4308383485 isParatext "false" @default.
• W4308383485 isRetracted "false" @default.
• W4308383485 workType "article" @default.